Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lamotrigine: pharmacokinetics

W R Garnett1

  • 1Department of Pharmacy, Virginia Commonwealth University, Medical College of Virginia, Richmond 23298-0533, USA.

Journal of Child Neurology
|January 16, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical implications of drug interactions with coxibs.

Pharmacotherapy·2001
Same author

Treatment of Crohn's disease with infliximab.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2001
Same author

Coprescribing proton pump inhibitors with other medications.

Managed care interface·2001
Same author

Antiepileptic drug treatment: outcomes and adherence.

Pharmacotherapy·2000
Same author

Clinical pharmacology of topiramate: a review.

Epilepsia·2000
Same author

Effect of over-the-counter cimetidine on phenytoin concentrations in patients with seizures.

The Annals of pharmacotherapy·1999
Same journal

Birmingham, 1963.

Journal of child neurology·2026
Same journal

Hyperintensity on Diffusion-Weighted Imaging in a MELAS Patient Does Not Necessarily Mean Cytotoxic Edema.

Journal of child neurology·2026
Same journal

Neuromuscular Symptoms of <i>ORAI1</i>-Related Immunodeficiency.

Journal of child neurology·2026
Same journal

Symptoms of Obsessive-Compulsive Disorder, Attention-Deficit/Hyperactivity Disorder, and Autism Spectrum Disorder in Children and Adolescents Attending a Headache Outpatient Clinic and School-Based Controls.

Journal of child neurology·2026
Same journal

Acute Encephalopathy From Central Nervous System Hemophagocytic Lymphohistiocytosis (CNS HLH) in X-Linked Lymphoproliferative Disease Type 1 (XLP-1).

Journal of child neurology·2026
Same journal

The Cost of Fear for Pediatric Neurologic Care.

Journal of child neurology·2026
See all related articles

Lamotrigine demonstrates linear pharmacokinetics, with high bioavailability and minimal impact from food. Dosage adjustments may be needed in children and with certain interacting medications.

Area of Science:

  • Pharmacology
  • Clinical Pharmacy
  • Drug Metabolism

Background:

  • Understanding lamotrigine pharmacokinetics is crucial for optimizing epilepsy treatment.
  • Previous studies have investigated lamotrigine's absorption, distribution, metabolism, and excretion (ADME) in various populations.

Purpose of the Study:

  • To comprehensively review the pharmacokinetics of lamotrigine.
  • To analyze factors influencing lamotrigine's half-life and elimination.

Main Methods:

  • Review of single and multiple dose studies.
  • Analysis of data from animal models, healthy volunteers, and epilepsy patients.
  • Pharmacokinetic parameter assessment including bioavailability, volume of distribution, protein binding, and half-life.

Related Experiment Videos

Main Results:

  • Lamotrigine exhibits first-order linear pharmacokinetics with near 100% bioavailability.
  • Absorption is unaffected by food; no first-pass metabolism observed.
  • Half-life ranges from 24.1 to 35 hours in adults, influenced by enzyme-inducing/inhibiting drugs; no autoinduction or saturable metabolism found.
  • Children eliminate lamotrigine faster than adults, with younger children showing more rapid elimination.

Conclusions:

  • Lamotrigine's pharmacokinetic profile is predictable and linear.
  • Age-related differences in lamotrigine elimination exist, particularly in pediatric populations.
  • Potential for drug interactions necessitates careful consideration in clinical practice.